In vitro effect of glucagon-like peptide-1 (7-36)amide, oxyntomodulin, vasoactive intestinal peptide and somatostatin on gastric acid and pepsinogen secretion.
Ben-Hamida
A
A
Department of Surgery, Royal Postgraduate Medical School, London, UK.
Houssein
A A
AA
Man
W K
WK
Spencer
J
J
D000632:Aminopyrine / Q000378:metabolism; D000818:Animals; D002927:Cimetidine / Q000494:pharmacology; D005744:Gastric Acid / Q000378:metabolism*; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides / Q000494:pharmacology*; D006632:Histamine / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D008297:Male; D053772:Oxyntomodulin; D010435:Pepsinogens / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013004:Somatostatin / Q000494:pharmacology*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D006635:Histamine H2 Antagonists; D053772:Oxyntomodulin; D010435:Pepsinogens; D010455:Peptides; D000632:Aminopyrine; D014660:Vasoactive Intestinal Peptide; D013004:Somatostatin; D004763:Glucagon-Like Peptides; D002927:Cimetidine; D006632:Histamine; D052216:Glucagon-Like Peptide 1